READ OUR STORY
Etna Biotech, a Zydus Vaccine research centre in Catania, Italy
Etna Biotech is a vaccine research center headquartered in Catania. Start up of the former Swiss Serum and Vaccine Institute, later Berna Biotech, Etna Biotech is a company whose key competencies lie in researching and developing vaccines and immunotherapeutics for infectious diseases and other chronic illnesses.
Etna Biotech was funded in 2001 and has been acquired in 2008 by the Zydus and is one of the two state-of-the-art R&D centers of the Vaccine Technology Centre (VTC) in India, the vaccine division of Zydus Group.
Etna Biotech is fully integrated in the Zydus Group and operates in tight collaboration with the Vaccine Technology Center, applying cutting edge technologies for the early stage vaccine research.
Etna Biotech has participated in previuos FP programmes and currently is involved in FP7 and H2020 programme of the EU, as well as in national grant programmes funded by EU.
Zydus Lifesciences Limited, the parent company of Etna Biotech, is a fully integrated, global healthcare provider located in Ahmedabad, India. With a legacy of over 70 years, the company is driven by a passion for innovation and making a difference in the world of health and care. Zydus Lifesciences is India’s fourth largest pharmaceutical company with more than 30 manufacturing plants worldwide and business operations in 55 countries including, India, the US, France, Spain, Brazil, Mexico, and South Africa. As one of the key players amongst pharmaceutical manufacturing companies, Zydus Lifesciences has manufacturing capabilities across the entire pharmaceutical value chain including formulations, APIs, vaccines, biosimilars, complex products, animal health products, and wellness products. From new chemical entities to vaccines, biosimilars, novel biologics, and niche technologies, Zydus is exploring different ideas to develop differentiated medicines for the future. Zydus Lifescience’s ZyCoV-D vaccine was the world’s first plasmid DNA vaccine to be approved for human use and is currently approved in India as a two-dose regimen for adults and children aged 12 years and above. Zydus Lifesciences continues to innovate with an unswerving focus to address unmet healthcare needs and is dedicated to its mission of creating healthier, happier communities across the globe.
For more information, please visit www.zyduslife.com.